A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview We are a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. On March 26, 2025, we announced that our lead product candidate, VYKATTM XR (diazoxide choline) extended-release tablets, formerly known as DCCR, had been approved by the U.S. Food and Drug Administration (FDA). VYKAT XR is indicated to treat hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). On April 14, 2025, we announced that prescriptions of VYKAT XR had been delivered to the first individuals living with PWS who had been prescribed the medication and began recognizing revenue from the sales of VYKAT XR during the three months ended June 30, 2025. We are incorporated in the State of Delaware and headquartered in Redwood City, California. VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator.
| Metric | TTM | FY2025 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|
| Revenue | 190M | 190M | - | - | 0 | 3.0M |
| Net Income | 20M | 20M | -16M | -16M | -13M | - |
| EPS | $0.39 | $0.39 | $-75.75 | $-126.75 | $-781.50 | $-519.00 |
| Free Cash Flow | 47M | 47M | -14M | -10M | -4.5M | -886K |
| ROIC | 2.2% | 9.5% | -313.0% | -298.0% | -61.5% | - |
| Gross Margin | 98.6% | 98.6% | - | - | - | - |
| Debt/Equity | 0.11 | 0.11 | 0.62 | 1.54 | -0.00 | -0.41 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 9.4M | 9.4M | -14M | -12M | -5.2M | -847K |
| Operating Margin | 4.9% | 4.9% | - | - | - | -28.2% |
| ROE | 4.5% | 5.9% | -472.0% | -493.5% | - | - |
| Shares Outstanding | 53M | 53M | 1M | 1M | 0M | 0M |
| Metric | 2013 | 2014 | 2015 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 3.0M | 0 | N/A | N/A | 190M | 190M |
| Gross Margin | N/A | N/A | N/A | N/A | 98.6% | 98.6% |
| R&D | 2.4M | 2.2M | 4.5M | 5.2M | 41M | 41M |
| SG&A | 1.5M | 2.7M | 6.1M | 6.7M | 132M | 132M |
| EBIT | -847K | -5.2M | -12M | -14M | 9.4M | 9.4M |
| Op. Margin | -28.2% | N/A | N/A | N/A | 4.9% | 4.9% |
| Net Income | N/A | -13M | -16M | -16M | 20M | 20M |
| Net Margin | N/A | N/A | N/A | N/A | 10.8% | 10.8% |
| Non-Recurring | -1K | -8K | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | N/A | -61.5% | N/M | N/M | 9.5% | 2.2% |
| ROE | N/A | N/A | -493.5% | -472.0% | 5.9% | 4.5% |
| ROA | N/A | -265.2% | -194.0% | -228.3% | 4.6% | 3.6% |
| Cash Flow | ||||||
| Op. Cash Flow | -885K | -4.5M | -10M | -13M | 47M | 47M |
| Free Cash Flow | -886K | -4.5M | -10M | -14M | 47M | 47M |
| Owner Earnings | -942K | -5.0M | -11M | -15M | -1.1M | -1.1M |
| CapEx | 1K | 31K | 56K | 39K | 73K | 73K |
| Maint. CapEx | 42K | 161K | 108K | 132K | 2.0M | 2.0M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 42K | 161K | 108K | 132K | 2.0M | 2.0M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.2% | 0.2% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 100M | 100M |
| Buyback Yield | N/A | N/A | N/A | N/A | 4.0% | 3.6% |
| Stock-Based Comp | 14K | 345K | 942K | 871K | 46M | 46M |
| Debt Repayment | 0 | 0 | 0 | 0 | 62K | 62K |
| Balance Sheet | ||||||
| Net Debt | 13M | -8.0M | N/A | N/A | -256M | -20M |
| Cash & Equiv. | 1.3M | 8.0M | 5.5M | 2.7M | 70M | 70M |
| Long-Term Debt | N/A | N/A | N/A | N/A | 50M | 50M |
| Debt/Equity | -0.41 | -0.00 | 1.54 | 0.62 | 0.11 | 0.11 |
| Interest Coverage | -0.3 | -1.2 | N/A | N/A | 1.7 | 1.7 |
| Equity | -34M | -11M | 3.2M | 3.4M | 450M | 450M |
| Total Assets | 1.6M | 8.4M | 8.2M | 5.6M | 564M | 564M |
| Total Liabilities | 36M | 20M | 5.0M | 2.1M | 114M | 114M |
| Intangibles | 49K | 0 | 993K | 943K | 9.7M | 9.7M |
| Retained Earnings | -57M | -70M | -86M | -98M | -431M | -431M |
| Working Capital | -13M | 7.0M | 3.2M | 2.1M | 294M | 294M |
| Current Assets | 1.5M | 8.3M | 6.4M | 3.8M | 356M | 356M |
| Current Liabilities | 14M | 1.3M | 3.2M | 1.7M | 61M | 61M |
| Per Share Data | ||||||
| EPS | -519.00 | -781.50 | -126.75 | -75.75 | 0.39 | 0.39 |
| Owner EPS | -131.85 | -55.30 | -17.93 | -22.91 | -0.02 | -0.02 |
| Book Value | -4,787.65 | -123.98 | 5.09 | 5.43 | 8.57 | 8.57 |
| Cash Flow/Share | -123.94 | -49.69 | -16.27 | -21.32 | 0.89 | 0.43 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.0M | 0.1M | 0.6M | 0.6M | 52.5M | 52.5M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | 122.2 | 134.9 |
| P/FCF | N/A | N/A | N/A | N/A | 53.5 | 59.1 |
| EV/EBIT | N/A | N/A | N/A | N/A | 238.6 | 291.3 |
| Price/Book | N/A | N/A | 30.0 | 10.2 | 5.6 | 6.1 |
| Price/Sales | N/A | N/A | N/A | N/A | 17.5 | 14.5 |
| FCF Yield | N/A | -39.7% | -10.7% | -38.5% | 1.9% | 1.7% |
| Market Cap | N/A | 11M | 97M | 35M | 2.5B | 2.8B |
| Avg. Price | N/A | 212.14 | 250.74 | 84.35 | 63.32 | 52.62 |
| Year-End Price | N/A | 126.00 | 153.00 | 55.50 | 47.65 | 52.62 |
SOLENO THERAPEUTICS INC passes 3 of 9 quality checks, indicating weak fundamentals.
SOLENO THERAPEUTICS INC trades at 134.9x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 58.1x vs a median of 53.5x. The company's 5-year average gross margin is 98.6%. Total shareholder yield (buybacks) is 3.6%.
SOLENO THERAPEUTICS INC (SLNO) has a current P/E ratio of 134.9, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
SOLENO THERAPEUTICS INC (SLNO) has a 5-year average return on invested capital (ROIC) of -26.0%. This is below average and may indicate limited pricing power.
SOLENO THERAPEUTICS INC (SLNO) has a market capitalization of $2.8B. It is classified as a mid-cap stock.
SOLENO THERAPEUTICS INC (SLNO) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 3.63%.
Based on historical P/E analysis, SOLENO THERAPEUTICS INC (SLNO) appears expensive. The current P/E of 134.9 is 799% above its historical median of 15.0.
SOLENO THERAPEUTICS INC (SLNO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
SOLENO THERAPEUTICS INC (SLNO) reported annual revenue of $190 million in its most recent fiscal year, based on SEC EDGAR filings.
SOLENO THERAPEUTICS INC (SLNO) has a net profit margin of 10.8%. This is a healthy margin.
SOLENO THERAPEUTICS INC (SLNO) generated $47 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
SOLENO THERAPEUTICS INC (SLNO) has a debt-to-equity ratio of 0.11. This indicates a conservatively financed balance sheet.
SOLENO THERAPEUTICS INC (SLNO) reported earnings per share (EPS) of $0.39 in its most recent fiscal year.
SOLENO THERAPEUTICS INC (SLNO) has a return on equity (ROE) of 5.9%. This indicates moderate shareholder returns.
SOLENO THERAPEUTICS INC (SLNO) has a 5-year average gross margin of 98.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for SOLENO THERAPEUTICS INC (SLNO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SOLENO THERAPEUTICS INC (SLNO) has a book value per share of $8.57, based on its most recent annual SEC filing.